Capricor surges on plans to seek FDA approval for lead asset [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
The San Diego, California-based biotech said it would begin the filing of a biologics license application (BLA) in October targeting FDA approval for deramiocel in cardiomyopathy associated with the neuromuscular disorder Duchenne muscular dystrophy (DMD). The company added that findings from its Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) trials compared to historical data are expected to support the submission. Additionally, Capricor ( CAPR ) announced changes to its Phase 3 HOPE-3 clinical trial, noting plans to expand the drug's label for DMD skeletal muscle myopathy after a potential approval. As a result, the company said it would no longer unblind Cohort A of the study and instead combine Cohorts A and B to advance HOPE-3 as a post-approval study. Recommended For You More Trending News Recommended For You More Trending News About CAPR Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Maxim Group from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Wave's stock swells as it eyes approval following Phase II DMD victory [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyGlobeNewswire
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.MarketBeat
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Sec Filings
- 9/24/24 - Form SC
- 9/24/24 - Form 4
- 9/24/24 - Form 8-K
- CAPR's page on the SEC website